米国臨床腫瘍学会（American Society of Clinical Oncology）

日本臨床腫瘍学会

国際胃癌学会(International Gastric Cancer Association)

日本胃癌学会

日本緩和医療学会

日本癌治療学会

日本癌学会

東京がん化学療法研究会

日本内科学会

日本消化器内視鏡学会

日本消化器病学会

Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study

Ryohei Kawabata, Keisho Chin, Daisuke Takahari, Hisashi Hosaka, Osamu Muto, Yoshiaki Shindo, Naoki Nagata, Hiroshi Yabusaki, Hiroshi Imamura, Shunji Endo, Tomomi Kashiwada, Masato Nakamura, Jun Hihara, Michiya Kobayashi, Tamotsu Sagawa, Soh Saito, Atsushi Sato, Takeshi Yamada, Naohiro Okano, Ken Shimada, Masashi Matsushima, Masato Kataoka, Shigemi Matsumoto, Masahiro Goto, Masahito Kotaka, Takeshi Shiraishi, Hiromichi Yamai, Fumio Nagashima, Naoki Ishizuka, Kensei Yamaguchi

Gastric Cancer   26 ( 6 )   1020 - 1029   2023.8

Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy

Junichi Nakagawa， Takenori Takahata， Yu Chen， Kensuke Saito， Kosuke Kamata， Takuto Tachita，Satoru Yamashita， Keigo Saito， Kayo Ueno， Atsushi Sato， Hirotake Sakuraba， Takenori Niioka

Cancer Chemother Pharmacol   92 ( 5 )   391 - 398   2023.8

アントラサイクリン系抗がん剤の血管外漏出にデクスラゾキサンを使用した4例の報告

高畑武功，佐藤　温，照井一史，中原潤一，兵頭　塁，粟津朱美，阿保恵美子，蓮井研吾，陳　豫，斎藤絢介，佐々木洸太

癌と化学療法   50 ( 4 )   467 - 471   2023.4

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603

Yasuyuki Kawamoto, Satoshi Yuki, Kentaro Sawada, Michio Nakamura, Osamu Muto, Susumu Sogabe, Yoshiaki Shindo, Atsushi Ishiguro, Atsushi Sato, Yasushi Tsuji, Masayoshi Dazai, Hiroyuki Okuda, Takashi Meguro, Kazuaki Harada, Mari Sekiguchi, Kazufumi Okada, Yoichi M Ito, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu

Oncologist   27 ( 8 )   e642 - e649   2022.8

Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer

Shintaro Nakano, Yasuyuki Kawamoto, Satoshi Yuki, Kazuaki Harada, Takuto Miyagishima, Susumu Sogabe, Masayoshi Dazai, Atsushi Sato, Atsushi Ishiguro, Michio Nakamura, Shinya Kajiura, Yasuo Takahashi, Miki Tateyama, Kazuteru Hatanaka, Yasushi Tsuji, Takahide Sasaki, Yoshiaki Shindo, Tomoe Kobayashi, Isao Yokota, Naoya Sakamoto, Yuh Sakata, Yoshito Komatsu

BMJ Open   12 ( 5 )   e048833 - e048833   2022.5

Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)

Yasuyuki Kawamoto, Satoshi Yuki, Takashi Meguro, Kazuteru Hatanaka, Minoru Uebayashi, Michio Nakamura, Hiroyuki Okuda, Ichiro Iwanaga, Takashi Kato, Shintaro Nakano, Atsushi Sato, Kazuaki Harada, Koji Oba, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu

27 ( 5 )   340-e374 - 340-e374   2022.5

Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer

Ken Ito, Satoshi Yuki, Hiroshi Nakatsumi, Yasuyuki Kawamoto, Kazuaki Harada, Shintaro Nakano, Rika Saito, Takayuki Ando, Kentaro Sawada, Masataka Yagisawa, Atsushi Ishiguro, Masayoshi Dazai, Ichiro Iwanaga, Kazuteru Hatanaka, Atsushi Sato, Ryusuke Matsumoto, Yoshiaki Shindo, Miki Tateyama, Tetsuhito Muranaka, Masaki Katagiri, Isao Yokota, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu

Support Care Cancer   2022.3

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.

Denda T, Takashima A, Gamoh M, Iwanaga I, Komatsu Y, Takahashi M, Nakamura M, Ohori H, Sakashita A, Tsuda M, Kobayashi Y, Baba H, Kotake M, Ishioka C, Yamada Y, Sato A, Yuki S, Morita S, Takahashi S, Yamaguchi T, Shimada K

154   296 - 306   2021.9

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report

Sasaki K, Yokota Y, Isojima T, Fujii M, Hasui K, Y Chen, Saito K, Takahata T, Kindaichi S, Sato A

Asian Pacific Society of Respirology   9 ( 7 )   2021.9

Multicenter Analysis of Hand Foot Syndrome by CapeOx Therapy Using Telephone Support Program after Radical Colon Cancer Surgery

Junichi Koike, Kaoru Furushima, Shin Sasaki, Atsushi Satoh, Kazuteru Watanabe, Mitsunori Ushigome, Tomoaki Kaneko, Hiroyuki Shiokawa, Satoru Kagami, Mari Oba and Kimihiko Funahashi

74 ( 5 )   287 - 295   2021.5

Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.

Takahashi S, Sakamoto Y, Denda T, Takashima A, Komatsu Y, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Yuki S, Okita A, Ouchi K, Komine K, Watanabe M, Morita S, Ishioka C

Cancer science   112 ( 4 )   1567 - 1578   2021.4

Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy.

Nakagawa J, Takahata T, Hyodo R, Chen Y, Hasui K, Sasaki K, Saito K, Ueno K, Hosoi K, Terui K, Sato A, Niioka T

Scientific reports   11 ( 1 )   785   2021.1

nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients

M Ueno, T Ioka, A Sato, et al.

Cancer Medicine   24 ( 9 )   9396 - 9408   2020.10

A Case of Non-Resectable Pancreatic Cancer With Multiple Hepatic Metastases Treated With FOLFIRINOX Therapy and Conversion Surgery

Gan To Kagaku Ryoho   46 ( 13 )   2551 - 2553   2019.12

[A Case of Non-Resectable Pancreatic Cancer with Multiple Hepatic Metastases Treated with FOLFIRINOX Therapy and Conversion Surgery].

Akaishi T, Ishido K, Kimura N, Nagase H, Odagiri T, Fujita H, Chen Y, Saito K, Takahata T, Sato A, Hakamada K

Gan to kagaku ryoho. Cancer & chemotherapy   46 ( 13 )   2551 - 2553   2019.12

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.

Atsuo Takashima, Kohei Shitara, Kazumasa Fujitani, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yutaka Kimura, Kenji Amagai, Hirofumi Fujii, Kei Muro, Taito Esaki, Yasuhiro Choda, Toshimi Takano, Keisho Chin, Atsushi Sato, Masahiro Goto, Norimasa Fukushima, Takuo Hara, Nozomu Machida, Manabu Ohta, Narikazu Boku, Masashi Shimura, Satoshi Morita, Wasaburo Koizumi

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   22 ( 1 )   155 - 163   2019.1

癌化学療法施行患者における安全性評価と苦痛度評価の差異に関する患者因子の検討

佐藤温、高畑武功、斎藤絢介　他

癌と化学療法   45 ( 6 )   955 - 960   2018.6

[Analysis of the Patient Factors in the Difference between Adverse Effect Evaluation and Distress Evaluation in Cancer Patients Receiving Chemotherapy].

Tanaka K, Sato A, Takahata T, Kudo F, Saito K, Yu C

Gan to kagaku ryoho. Cancer & chemotherapy   45 ( 6 )   955 - 960   2018.6

GemcitabinおよびS-1治療抵抗性膵癌に対するWeekly Paclitaxel療法の後方視的検討

佐藤温、高畑武功、斎藤絢介、陳豫　

癌と化学療法   45 ( 5 )   817 - 821   2018.5

[Retrospective Analysis of Weekly Paclitaxel Chemotherapy for Gemcitabine- and S-1-Resistant Pancreatic Cancer].

Takahata T, Sato A, Yu C, Saito K

Gan to kagaku ryoho. Cancer & chemotherapy   45 ( 5 )   817 - 821   2018.5

A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors.

Sasaki T, Kato Y, Sato A, Usui N, Baba E, Takano T, Susumu N, Ohnishi K, Nishimoto H, Kiura K

Journal of pharmaceutical health care and sciences   4   2   2018

Health-related quality of life in a randomized phase Ⅲ study of gemcitabine plus S-1,S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer:GEST study.

Yasuhiro Hagiwara,Yasuo Ohashi　他

ESMO Open Cancer Horizons   2017.3

Assessment of Injection Site Reactions for Peripheral Intravenous Oxaliplatin Infusion and Potential Remedies.

Handa S, Kuroiwa R, Miyano M, Shimizu H, Kamei D, Takei H, Sonou H, Yamamoto H, Murayama J, Sato A, Kato Y

Gan to kagaku ryoho. Cancer & chemotherapy   43 ( 8 )   985 - 8   2016.8

[Withdrawal of Anticancer Therapy in Advanced Disease Because of Side Effects].

Sato A, Chin Y, Kudo F, Saito K, Takahata T

Gan to kagaku ryoho. Cancer & chemotherapy   43 ( 7 )   798 - 802   2016.7

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

Koichi Takayama,Shunichi Sugawara,Yasuo Saijo,Makoto Maemondo,Atsushi Sato,Shinzo Takamori,Taishi Harada,Tetsuro Sasada,Tatsuyuki Kakuma,Junji Kishimoto,Akira Yamada,Masanori Noguchi,Kyogo Itoh,and Yoichi Nakanishi

Journal of Immunology Reseach   7 - 7   2016.1

A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).

Yoshida M, Takagane A, Miyake Y, Shimada K, Nagata N, Sato A, Ogata Y, Fukunaga M, Otsuka K, Takahashi T, Matsumoto H, Kagimura T, Tsuji A

Oncology   91 ( 1 )   24 - 30   2016

Study protocol of the TRICOLORE trial:a randomized phase Ⅲ study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1,irinotecan,and bevacizumab as first-line therapy for metastatic colorectal cancer.

Yoshito Komatsu、Chikashi Ishioka、Ken Shimada、Yasuhide Yamada、Makio Gamoh、Atsushi Sato、Tatsuro Yamaguchi、Satoshi Yuki、Satoshi Morita、Shin Takahashi、Rei Goto and Minoru Kurihara

BMC Cancer 2015 Vol.15   15   626 - 626   2015.9

A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.

Nakayama N, Sato A, Tanaka S, Shimada K, Konishi K, Sasaki E, Hibi K, Ichikawa H, Kikuchi Y, Sakuyama T, Sekikawa T, Hayashi K, Nishina H, Tokyo Cooperative Oncology Group, Tokyo, Japan.

Investigational new drugs   33 ( 4 )   954 - 62   2015.8

A phase Ⅱ study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer:the TCOG-GI 0802 study.

Nakayama N、Sato A、Tanaka S、Shimada K、Konishi K、Sasaki E、Hibi K、Ichikawa H、Kikuchi Y、Sakuyama T、Sekikawa T、Hayashi K、Nishina H

Invest New Drugs 2015 Aug 33(4)   33 ( 4 )   954 - 962   2015.5

[Second-line chemotherapy for advanced pancreatic cancer].

Sato A, Saito K, Takahata T

Gan to kagaku ryoho. Cancer & chemotherapy   42 ( 4 )   403 - 7   2015.4

[Introduction of oxaliplatin for treating unresectable advanced or recurrent gastric cancer in clinical practice].

Sato A

Gan to kagaku ryoho. Cancer & chemotherapy   42 ( 4 )   443 - 6   2015.4

[Topoisomerase II inhibitors (anthracyclines)].

Sato A, Takahata T, Saito K

Nihon rinsho. Japanese journal of clinical medicine   73 Suppl 2   178 - 83   2015.2

[Microtubule polymerization inhibitors].

Takahata T, Sato A, Saito K, Yamagata K

Nihon rinsho. Japanese journal of clinical medicine   73 Suppl 2   162 - 6   2015.2

[Use of granulocyte-colony stimulating factor(G-CSF)in patients with cancer at high risk of febrile neutropenia on the basis of high age and complications, recommendations for patients receiving radiotherapy, and adverse events because of G-CSF].

Hanada N, Tanaka S, Takahata T, Sato A

Gan to kagaku ryoho. Cancer & chemotherapy   41 ( 6 )   702 - 6   2014.6

A Prospective Observational Study to Examine the Relationship between Quality of Life and Adverse Events of First-line Chemotherapy Plus Cetuximab in Patients with KRAS Wild-type Unresectable Metastatic Colorectal Cancer: QUACK Trial.

Ooki A, Ando M, Sakamoto J, Sato A, Fujii H, Yamaguchi K.

Japan Journal Clinical   44 ( 4 )   383 - 387   2014.2

肝転移を伴う切除不能胆管癌に対して化学療法が著効した1例

脇屋太一,豊木嘉一,石戸圭之輔,工藤大輔,木村憲央,矢越雄太,石黒敦,高畑武功,佐藤温,袴田健一

癌と化学療法   40 ( 12 )   1753 - 1755   2013.11

[A case of unresectable biliary tract cancer with liver metastasis that exhibited an effective response to chemotherapy].

Wakiya T, Toyoki Y, Ishido K, Kudo D, Kimura N, Yakoshi Y, Ishiguro A, Takahata T, Sato A, Hakamada K

Gan to kagaku ryoho. Cancer & chemotherapy   40 ( 12 )   1753 - 5   2013.11

Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, Tomotaka Shimamura, Masayuki Sho, Masayuki Kitano, Ann-Lii Cheng, Kazuhiro Mizumoto, Jen-Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Sato, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka

Journal of clinical oncology : official journal of the American Society of Clinical Oncology   31 ( 13 )   1640 - 1648   2013.5

Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.

Kensei Yamaguchi, Akira Sawaki, Toshihiko Doi, Taroh Satoh, Yasuhide Yamada, Yasushi Omuro, Tomohiro Nishina, Narikazu Boku, Keisho Chin, Yasuo Hamamoto, Hiroya Takiuchi, Yoshito Komatsu, Shigehira Saji, Wasaburo Koizumi, Yoshinori Miyata, Atsushi Sato, Eishi Baba, Takao Tamura, Takashi Abe, Atsushi Ohtsu

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   16 ( 2 )   175 - 182   2013.4

Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.

Yamaguchi K1, Sawaki A, Doi T, Satoh T, Yamada Y, Omuro Y, Nishina T, Boku N, Chin K, Hamamoto Y, Takiuchi H, Komatsu Y, Saji S, Koizumi W, Miyata Y, Sato A, Baba E, Tamura T, Abe T, Ohtsu A.

Gastric Cancer   16 ( 2 )   175 - 182   2013.4

Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.

Yamaguchi K, Sawaki A, Doi T, Satoh T, Yamada Y, Omuro Y, Nishina T, Boku N, Chin K, Hamamoto Y, Takiuchi H, Komatsu Y, Saji S, Koizumi W, Miyata Y, Sato A, Baba E, Tamura T, Abe T, Ohtsu A

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   16 ( 2 )   175 - 82   2013.4

[A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow (DCBM)due to bone metastasis, with DIC recovery by administration of S-1 and docetaxel].

Hiromi Imataka, Atsushi Sato, Kazuyuki Hamada, Norikazu Takeda, Hiroshi Nemoto

Gan to kagaku ryoho. Cancer & chemotherapy   40 ( 2 )   241 - 243   2013.2

[A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow (DCBM)due to bone metastasis, with DIC recovery by administration of S-1 and docetaxel].

Imataka H, Sato A, Hamada K, Takeda N, Nemoto H

Gan to kagaku ryoho. Cancer & chemotherapy   40 ( 2 )   241 - 3   2013.2

[Medical treatment for gastrointestinal stromal tumor (GIST) in Japan].

Sato A, Hamada K, Imataka H

Gan to kagaku ryoho. Cancer & chemotherapy   39 ( 5 )   708 - 12   2012.5

[Skin toxicity].

Sato A, Hamada K, Imataka H

Gan to kagaku ryoho. Cancer & chemotherapy   38 ( 11 )   1767 - 72   2011.11

[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].

Atsushi Sato, Toshihiko Doi, Narikazu Boku, Ken Kato, Yoshito Komatsu, Kensei Yamaguchi, Kei Muro, Yasuo Hamamoto, Wasaburo Koizumi, Nobuyuki Mizunuma, Hiroya Takiuchi

Gan to kagaku ryoho. Cancer & chemotherapy   38 ( 4 )   561 - 569   2011.4

[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].

Sato A, Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, Hamamoto Y, Koizumi W, Mizunuma N, Takiuchi H

Gan to kagaku ryoho. Cancer & chemotherapy   38 ( 4 )   561 - 9   2011.4

Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.

Toshihiko Doi, Narikazu Boku, Ken Kato, Yoshito Komatsu, Kensei Yamaguchi, Kei Muro, Yasuo Hamamoto, Atsushi Sato, Wasaburo Koizumi, Nobuyuki Mizunuma, Hiroya Takiuchi

Japanese journal of clinical oncology   40 ( 10 )   913 - 920   2010.10

アミオダロン塩酸塩速崩錠「ＴＨ｝の健康成人における薬物動態

高野和彦，長井晶彦，佐藤隆，佐藤温

診療と新薬   47 ( 9 )   898 - 903   2010.9

[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Japanese patients with bone metastases--The Japanese version of the EORTC QLQ-BM22].

Takefumi Satoh, Kunihiko Kobayashi, Taisuke Hori, Shinsuke Iida, Atsushi Sato, Hiroshi Ishiguro, Edward Chow, Kojiro Shimozuma

Gan to kagaku ryoho. Cancer & chemotherapy   37 ( 8 )   1507 - 1512   2010.8

[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Japanese patients with bone metastases--The Japanese version of the EORTC QLQ-BM22].

Satoh T, Kobayashi K, Hori T, Iida S, Sato A, Ishiguro H, Chow E, Shimozuma K

Gan to kagaku ryoho. Cancer & chemotherapy   37 ( 8 )   1507 - 12   2010.8

[Clinical development of oral chemotherapeutic agents for advanced gastric cancer].

Sato A, Nakamachi M, Imataka H, Hamada K

Gan to kagaku ryoho. Cancer & chemotherapy   37 ( 7 )   1192 - 7   2010.7

Quality of guideline development assessed by the Evaluation Committee of the Japan Society of Clinical Oncology.

Takuro Shimbo, Tsuguya Fukui, Chikashi Ishioka, Kohji Okamoto, Takahiro Okamoto, Shingo Kameoka, Atsushi Sato, Masakazu Toi, Kunihiko Matsui, Toshihiko Mayumi, Shigetoyo Saji, Masaru Miyazaki, Yuichi Takatsuka, Koichi Hirata

International journal of clinical oncology   15 ( 3 )   227 - 233   2010.6

Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.

Wasaburo Koizumi, Toshikazu Akiya, Atsushi Sato, Toshikazu Sakuyama, Eisaku Sasaki, Takashi Tomidokoro, Tsutomu Hamada, Mototsugu Fujimori, Yoshinori Kikuchi, Ken Shimada, Tetsuya Mine, Kensei Yamaguchi, Tsuneo Sasaki, Minoru Kurihara

Cancer chemotherapy and pharmacology   65 ( 6 )   1093 - 1099   2010.5

アミオダロン塩酸塩速崩錠100mg{TH」及びアミオダロン塩酸塩速崩錠50mg「TH」の生物学的同等性試験

蓮沼智子，豊田幹男，土持一郎，小林亮一，佐藤　隆，佐藤　温

診療と新薬   47 ( 4 )   369 - 379   2010.4

The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer.

Yoko Ishihara, Kenichi Matsunaga, Hiroko Iijima, Go Hasegawa, Toshimitsu Suzuki, Atsushi Sato, Tomowo Kobayashi, Meng Yang, Robert M Hoffman

Anticancer research   30 ( 2 )   403 - 408   2010.2

[First/second/third-line chemotherapy with molecular targeted drugs for colorectal cancer].

Sato A, Nakamachi M, Imataka H

Gan to kagaku ryoho. Cancer & chemotherapy   36 ( 8 )   1242 - 6   2009.8

[Gastric cancer].

Sato A, Nakamachi M

Gan to kagaku ryoho. Cancer & chemotherapy   36 ( 2 )   176 - 81   2009.2

A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer.

Yoshikawa T, Tsuburaya A, Shimada K, Sato A, Takahashi M, Koizumi W, Yoshizawa Y, Nabeshima K, Kimura M, Hataya K, Kobayashi O

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   12 ( 4 )   212 - 8   2009

[Clinical development of chemotherapy for advanced gastric cancer].

Sato A, Nakamachi M

Gan to kagaku ryoho. Cancer & chemotherapy   35 ( 9 )   1461 - 6   2008.9

[A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer].

Suenaga M, Nishina T, Hyodo I, Munakata M, Koizumi W, Mishima H, Sato A, Mizunuma N, Hatake K

Gan to kagaku ryoho. Cancer & chemotherapy   35 ( 2 )   255 - 60   2008.2

[Clinical development of chemotherapy for advanced gastric cancer].

Sato A, Matsukawa M

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology   104 ( 2 )   186 - 93   2007.2

[Irinotecan chemotherapy for patients with advanced or relapsed pancreatic neoplasm].

Sekikawa T, Akaike A, Ushio J, Sato A, Matsukawa M

Nihon rinsho. Japanese journal of clinical medicine   64 Suppl 1   203 - 6   2006.1

[Pilot-testing of the Japanese version of the EORTC QLQ-STO22 gastric cancer module].

Morita S, Shimozuma K, Sato A, Nakamachi M, Blazeby J, West K, Fukuhara S, Sakamoto J

Gan to kagaku ryoho. Cancer & chemotherapy   31 ( 8 )   1195 - 9   2004.8

A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer.

Kondo Y, Terashima M, Sato A, Taguchi T

Japanese journal of clinical oncology   34 ( 4 )   195 - 201   2004.4

[Treatment of elderly patients with colorectal cancer].

Sato A, Shimada K, Sakashita A, Taguchi S

Nihon rinsho. Japanese journal of clinical medicine   61 Suppl 7   552 - 6   2003.9

[Mucositis].

Sato A, Sakashita A, Taguchi S

Nihon rinsho. Japanese journal of clinical medicine   61 ( 6 )   959 - 65   2003.6

[Hypersensitivity reactions to cancer chemotherapeutic agents].

Sato A, Sakashita A, Taguchi S

Gan to kagaku ryoho. Cancer & chemotherapy   30 ( 6 )   793 - 800   2003.6

[Chemotherapy of gastric cancer--a review of clinical trials in Japan].

Sato A, Ito T, Tomita T, Nakamura A, Taguchi S

Gan to kagaku ryoho. Cancer & chemotherapy   29 ( 9 )   1522 - 31   2002.9

[Individuated molecular target chemotherapy].

Yamamoto W, Endo W, Sato A, Matsukawa M

Nihon rinsho. Japanese journal of clinical medicine   60 ( 1 )   168 - 73   2002.1

Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens.

Sato A, Shimada K, Nakamachi M, Ushio J, Yamamoto W, Kurihara M, Matsukawa M

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   5 ( 4 )   233 - 6   2002

胃がん薬物療法Q&A

佐藤温（ Role： Edit）

ヴァンメディカル  2015.12 

改訂版がん化学療法副作用対策ハンドブック

岡本るみ子、佐々木常雄（ Role： Joint author）

羊土社  2015.11 

入門腫瘍内科学　改訂第2版

日本臨床腫瘍学会　監修（ Role： Joint author）

篠原出版新社  2015.3 

オンコロジークリニカルガイド　消化器癌化学療法　改訂4版

大村健二　編（ Role： Joint author）

南山堂  2014.11 

消化器病診療　第2版

一般財団法人　日本消化器病学会　監修（ Role： Joint author）

医学書院  2014.10 

がん患者の輸液・栄養療法

大村健二　編（ Role： Joint author）

南山堂  2014.9 

緩和医療学　日本緩和医療学会編集

日本緩和医療学会　編集（ Role： Joint author）

南山堂  2014.7 

抗がん薬の臨床薬理

相羽惠介（ Role： Joint author）

南山堂  2013.10 

Ｇ-ＣＳＦ（顆粒球コロニー刺激因子）の基礎と臨床

東條有伸　編集，佐藤　温ほか（ Role： Joint author）

医薬ジャーナル社  2013.7 

進行再発胃がんに対するがん化学療法のマネジメント

佐藤温

胃がんperspective Vol.8 No.3   8 ( 3 )   62 - 67   2016.2

ファーストライン化学療法を終えたとき、次治療の選択は？

斎藤絢介、佐藤温

臨床腫瘍プラクティス　Vol.12 No.1   12 ( 1 )   5 - 9   2016.2

特集　Second-Line Therapyの進歩　切除不能進行膵癌のセカンドライン化学療法

佐藤温、斎藤絢介、高畑武功

癌と化学療法 Vol.42 No.4   42 ( 4 )   403 - 407   2015.4

特別寄稿　治癒切除不能な進行・再発の胃癌に対するオキサリプラチンの臨床導入に当たって

佐藤温

癌と化学療法　Vol.42 No.4   42 ( 4 )   443 - 446   2015.4

胃がん薬物療法における分子標的薬の現状

高畑武功,田中諭,佐藤温

癌の臨床Vol.61 No.1   61 ( 1 )   23 - 27   2015.3

ハイリスクグループ（高齢者・合併症を有する患者）に対するG-CSF使用、放射線併用時の注意点およびG-CSFの有害反応

花田直之,田中諭,高畑武功,佐藤温

癌と化学療法Vol.41 No.6 2014   41 ( 6 )   702 - 706   2014.6

胃癌術後補助化学療法を完遂させるためにー副作用へのセルフケアでアドヒアランスを維持ー

佐藤　温

ALPHA CLUB   ( 382 )   2 - 3   2014.4

胃癌術後補助化学療法を完遂させるためにー患者の主体的な服薬（アドヒアランス）が完遂に導くー

佐藤　温

ALPHA CLUB   ( 381 )   2 - 3   2014.3

がん化学療法を受ける患者の副作用症状の緩和とその考え方についての一考察

佐藤　温

緩和ケア   24 ( 1 )   634 - 646   2014.1

【胃がん薬物治療の将来に向けて】 ここが知りたい胃がん薬物療法　現場ではどう対応しているのか?　ガイドラインで推奨されている薬を使い切った患者

佐藤温、高畑武功、花田直之、田中諭

臨床腫瘍プラクティス　   9 ( 2 )   162 - 168   2013.5

がん化学療法の薬-抗がん剤・ホルモン剤・分子標的薬-はや調べノート・パクリタキセル

佐藤　温

プロフェッショナルがんナーシング2013年別冊   142 - 143   2013.4

がん化学療法の薬-抗がん剤・ホルモン剤・分子標的薬-はや調べノート・ドセタキセル

佐藤　温

プロフェッショナルがんナーシング2013年別冊   146 - 147   2013.4

副作用対策のコツとピットフォール　癌治療による下痢とその対策

田中　諭，石黒　敦，高畑武功，佐藤　温

外来化学療法   4 ( 1 )   38 - 40   2013.2

【臨床現場が知りたい大腸がん薬物治療】key Drugを使い切った後のレジメン選択の考え方-Key Drug以外の薬剤を使用した治療

佐藤　温，高畑武功，石黒　敦，田中　諭

臨床腫瘍プラクティス   8 ( 4 )   385 - 389   2012.11

＜専門医の立場から＞治療ガイドラインから見る、胃癌薬物療法

佐藤　温

平成24年度通信教育講座　診療ガイドライン・薬剤コース　第5回　胃がん-補助化学療法の向上を目指して-   1 - 27   2012.10

【消化器がん化学療法レジメン】胃がん　胃癌化学療法　レジメン選択の基本

佐藤　温，高畑武功，石黒　敦，田中　諭

臨床腫瘍プラクティス　別冊II   35 - 39   2012.9

がんの悩み相談室　信仰・再発胃がん（Ｑ＆Ａ）

佐藤　温，会田龍治

ライフライン21がんの先進医療   6   33 - 35   2012.7

【比較的まれながんの化学療法-私の勧める化学療法-】ＧＩＳＴ（消化管間質腫瘍）の化学療法

佐藤　温，濱田和幸，今高博美

癌と化学療法   39 ( 5 )   708 - 712   2012.5

外来抗癌薬治療の実際　胃癌の外来化学療法

濱田和幸，今高博美，佐藤　温

外来化学療法   2 ( 3 )   178 - 182   2011.10

薬剤別胃癌化学療法における有害事象のコントロール　フッカピリミジン系薬剤

今高博美，濱田和幸，佐藤　温

消化器の臨床   14 ( 4 )   357 - 362   2011.8

大腸癌の分子標的治療薬を用いた薬物療法の実際　セカンドライン・サードラインで分子標的薬をどう使うか

濱田和幸，佐藤　温，中町正俊，今高博美

消化器の臨床   13 ( 5 )   533 - 538   2010.10

【経口薬によるがん治療の進歩】

佐藤　温，中町正俊，今高博美，濱田和幸

癌と化学療法   37 ( 7 )   1192 - 1197   2010.7

副作用対策のコツとピットフォール　アナフィラキシー

佐藤　温

外来化学療法   1 ( 1 )   34 - 35   2010.6

青森市立浪岡中学校　がん教育

2022.10.18

蓬田村立蓬田小学校　がん教育

2022.10.18

藤崎町立明徳中学校　がん教育

2022.07.05

患者との接し方

2022.04.09

がんと向き合う心構え

2022.04.02

オンライン市民公開フォーラム　がんと生きる - 進歩する医療が求める社会づくり -

2022.01.16

蓮田村立蓮田小学校　がん教育

2021.10.29

青森市立浪岡中学校　がん教育

2021.10.26

藤崎町立明徳中学校　がん教育

2021.10.01

がん教育オンライン地域交流会（北海道・東北地区）

2021.03.27

平内町立小湊中学校　がん教育

2020.11.17

八戸市立明治中学校　がん教育

2020.10.29

令和2年度指導者(高等学校)向けがん教育

2020.10.12

腫瘍内科におけるOnco-Cardiology~Medical Oncology の世界~

2020.02

腫瘍内科におけるがん患者のトータルケア

2020.01

市民公開講座　がんとともに歩むということ~いのちのはなし~

2019.12.07

弘前市立大和沢小学校　がん教育

2019.12.05

進行再発大腸がんにおける治療戦略

2019.12

大腸癌治療のこれまでとこれから

2019.11

がんプロ公開セミナー　~みんなで緩和ケアを考えよう~医療の構造からケアを考える

2019.11

学校ではじまったがん教育（長野県がん教育セミナー）

2019.10.27

国際医療福祉大学大学院　一般市民公開講座　多職種連携で挑むがんの緩和ケア：人生会議 (アドバンス・ケア・プランニング)： ACP)を考える　Medical Oncologist からの提言-意思決定を支援する-

2019.10.13

青森県立鶴田高等学校　がん教育

2019.10.10

青森県のがん教育　がん教育の在り方について、教育現場と共有したいこと

2019.10.08

がん医療に学ぶコミュニケーション～悪い知らせの伝え方～悪い知らせの伝え方

2019.10

市民公開講座　後悔しない選択のために～胃がんのことを知ろう～

2019.08

大腸癌薬物治療におけるコミュニケーション～患者支援に求められるスキル～

2019.07

五所川原市立第四中学校　がん教育

2019.06.06

がん治療において患者支援に求められるコミュニケーション

2019.06

がん医療に学ぶコミュニケーション～悪い知らせの伝え方～

2019.05

平成30年度~31年度青森県がんピア・サポート研修会

2019.02.02

胃癌薬物療法の変遷　~免疫チェックポイント阻害薬の開発まで~（三沢市立三沢病院）

2018.12.21

平川市立尾上中学校　がん教育

2018.12.06

鯵ヶ沢町立舞戸小学校　がん教育

2018.11.28

第21回弘前臨床腫瘍セミナー

2018.11

人生の最終段階における医療体制整備事業

2018.10

第4回東北腫瘍内科勉強会

2018.10

青森県立六戸高等学校　がん教育

2018.09.28

平成30年度弘前大学大学院医学研究科公開講座

2018.09 - 2019.09

第70回弘前癌治療懇話会

2018.09

第2回新潟病院医療連携講演会

2018.06

第20回弘前臨床腫瘍セミナー

2018.06

～聞いて話してがんのこと～出張ふらっとカフェin弘前市立図書館

2018.05

学術講演会～がん治療を再考する

2018.05

平成29年度青森県がんピア・サポート研修会　がんの基礎知識

2017.09.24

青森県がん・生活習慣対策課

2017.09

平成28年度青森県がんピア・サポート研修会　がんの基礎知識

2016.09.22

がん治療における患者支援を考えるワークショップ　Cancer Patient support

2015.03

第295回函館病院薬剤師会例会・学術講演会　がん専門薬剤師セミナー

2014.10

第32回薬剤師生涯セミナー　弘前薬薬連携委員会研修会

2014.10

協和発酵キリン勉強会

2014.09

第13回沖縄消化器癌懇談会

2014.09

金沢医科大学病院「第74回がん診療連携拠点病院研修会」

2014.03

「第7回九州大腸がん懇話会」

2014.02

「第17回つがる緩和医療を考える会」

2013.11

「黒石病院　第五回緩和医療勉強会」

2013.11

つがる市民公開講座

2013.11

弘前大学総合文化祭医学展特別講演

2013.10

「弘前大腸癌化学療法研究会」

2013.09

「山形大腸癌セミナー～高齢者の大腸癌治療について考える～」

2013.09

宮崎オンコロジーカンファレンス

2013.08

鹿児島大学緩和ケア学術講演会

2013.07

石巻がん化学療法セミナー

2013.05

第3回がん化学療法に伴う制吐療法研修会

2013.04

室蘭消化器癌懇話会

2013.04

西北五医師会　第490回集談会

2013.04